Evidence map›Paper›PMID 30175160›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2018

Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome.

Morgane Pihan, Stephen Keddie, Shirley D'Sa, Andrew J Church, Kwee L Yong, Mary M Reilly, Michael P Lunn

Open access · goldAbstract read
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 43 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Rasch-built overall disability scale for POEMS syndrome (POEMS-RODS).Journal of the peripheral nervous system : JPNS · 2022
    Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. 14th EUNOS Congress: PORTO, PORTUGAL, 16-19 JUNE 2019.Neuro-ophthalmology (Aeolus Press) · 2019
    Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Morgane PihanMRC Centre for Neuromuscular Diseases (M.P., S.K., M.M.R., M.P.L.), National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; Cancer Division (S.D., K.L.Y.), University College London Hospitals NHS Foundation Trust, London, UK; and Department of Neuroimmunology (A.J.C., M.P.L.), Institute of Neurology, Queen Square, London, UK.
Stephen KeddieMRC Centre for Neuromuscular Diseases (M.P., S.K., M.M.R., M.P.L.), National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; Cancer Division (S.D., K.L.Y.), University College London Hospitals NHS Foundation Trust, London, UK; and Department of Neuroimmunology (A.J.C., M.P.L.), Institute of Neurology, Queen Square, London, UK.
Shirley D'SaMRC Centre for Neuromuscular Diseases (M.P., S.K., M.M.R., M.P.L.), National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; Cancer Division (S.D., K.L.Y.), University College London Hospitals NHS Foundation Trust, London, UK; and Department of Neuroimmunology (A.J.C., M.P.L.), Institute of Neurology, Queen Square, London, UK.
Andrew J ChurchMRC Centre for Neuromuscular Diseases (M.P., S.K., M.M.R., M.P.L.), National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; Cancer Division (S.D., K.L.Y.), University College London Hospitals NHS Foundation Trust, London, UK; and Department of Neuroimmunology (A.J.C., M.P.L.), Institute of Neurology, Queen Square, London, UK.
Kwee L YongMRC Centre for Neuromuscular Diseases (M.P., S.K., M.M.R., M.P.L.), National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; Cancer Division (S.D., K.L.Y.), University College London Hospitals NHS Foundation Trust, London, UK; and Department of Neuroimmunology (A.J.C., M.P.L.), Institute of Neurology, Queen Square, London, UK.
Mary M ReillyMRC Centre for Neuromuscular Diseases (M.P., S.K., M.M.R., M.P.L.), National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; Cancer Division (S.D., K.L.Y.), University College London Hospitals NHS Foundation Trust, London, UK; and Department of Neuroimmunology (A.J.C., M.P.L.), Institute of Neurology, Queen Square, London, UK.
Michael P LunnMRC Centre for Neuromuscular Diseases (M.P., S.K., M.M.R., M.P.L.), National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; Cancer Division (S.D., K.L.Y.), University College London Hospitals NHS Foundation Trust, London, UK; and Department of Neuroimmunology (A.J.C., M.P.L.), Institute of Neurology, Queen Square, London, UK.
University College London Hospitals NHS Foundation Trust · GBUniversity College London · GB

Funding

Medical Research Council G0601943
6 · The paper itself

Abstract

objectiveTo investigate the sensitivity and the specificity of serum vascular endothelial growth factor (sVEGF) for the diagnosis of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome in patients with a neuropathy (NP) and to identify confounding causes of raised vascular endothelial growth factor (VEGF) in this context to improve accuracy.

methodsWe studied the specificity and sensitivity of sVEGF for the diagnosis of POEMS syndrome in a cohort of 195 consecutive patients with an NP in serum samples from June 2009 to November 2013, including 27 untreated patients with POEMS syndrome. We then studied VEGF in other neuropathies and analyzed causes of elevated VEGF in a multiple logistic regression analysis in a larger cohort of 236 patients including 168 with a non-POEMS NP and 68 without NP.

resultsThe sensitivity of elevated sVEGF for the diagnosis of POEMS was 100%. Its specificity was 91% in patients with an NP and 92% in patients with an NP and a paraproteinemia. sVEGF was much higher in POEMS before treatment. sVEGF was not significantly elevated in any non-POEMS NP or hematologic disease group. Multiple logistic regression showed that anemia with low iron was a significant predictor for elevated sVEGF and that chronic obstructive pulmonary disease (COPD) and obstructive sleep apnoea-hypopnoea syndrome were significant predictors for very elevated sVEGF.

interpretationWe confirmed the high sensitivity and specificity of an elevated VEGF for the diagnosis of POEMS. However, VEGF testing should be repeated, particularly after acute illnesses. Raised sVEGF should be interpreted with caution unless anemias with low iron, sleep apnea, COPD, cancers, vasculitis, and chronic inflammatory diseases are excluded. CLASSIFICATION OF EVIDENCE: This study provides class IV evidence that elevated sVEGF levels accurately identifies patients with POEMS syndrome.

Identifiers

PMID30175160
PMCPMC6117193
OpenAlexW2886450409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.